Article Versions Notes

Goutam S, Stukalin I, Ewanchuk B, Sander M, Ding PQ, Meyers DE, Heng D, Cheung WY, Cheng T. Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab. Current Oncology. 2022; 29(10):7695-7704. https://doi.org/10.3390/curroncol29100608

Goutam, Siddhartha, Igor Stukalin, Benjamin Ewanchuk, Michael Sander, Philip Q. Ding, Daniel E. Meyers, Daniel Heng, Winson Y. Cheung, and Tina Cheng. 2022. "Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab" Current Oncology 29, no. 10: 7695-7704. https://doi.org/10.3390/curroncol29100608

Goutam, S., Stukalin, I., Ewanchuk, B., Sander, M., Ding, P. Q., Meyers, D. E., Heng, D., Cheung, W. Y., & Cheng, T. (2022). Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab. Current Oncology, 29(10), 7695-7704. https://doi.org/10.3390/curroncol29100608